Favrille Company Description
Favrille hopes to bring personalized medicine to the masses. The biopharmaceutical company is set up to research, develop, and market immunotherapies for the treatment of cancer and other immune system diseases. Specifically, it has developed technology that could make personalized cancer therapies, derived from patients' own tumors, quicker and cheaper to produce. Its key product candidate, Specifid (formerly FavID), has been in trials to treat types of non-Hodgkin's lymphoma; however, development was halted in 2008 when the company's lead program, using Specific in concert with Genentech's cancer treatment Rituxan, failed.
View the Comprehensive Company Description for Favrille
The Company Description provides a historical perspective of Favrille's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Favrille's evolution in the marketplace.
